Adjuvant therapy in colorectal cancer. A randomized trial comparing radio-chemotherapy and radio-chemotherapy combined with methanol extraction residue of BCG, MER

E. Robinson, A. Bartal, Y. Cohen, David M. Milstein, T. Mekori

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Fifty-three patients with colorectal cancer (Dukes' B 2 and C) were randomized after surgery. One group was treated by radio-and/or chemotherapy and the second by radio-and/or chemotherapy and MER. After 24 and 36 months a significant longer disease free interval, lower recurrence rate and better survival was found in the group treated by radio-chemo-and immunotherapy. Treatment was well tolerated and there were few local side effects from the MER injections. The long time efficacy of this adjuvant treatment whether it increases the cure rate or only delays recurrence requires longer follow-up.

Original languageEnglish (US)
Pages (from-to)8-10
Number of pages3
JournalBiomedicine Express
Volume31
Issue number1
StatePublished - 1979
Externally publishedYes

Fingerprint

methanol extraction residue (MER) tubercle bacillus fraction
Radio
Methanol
Colorectal Neoplasms
Drug Therapy
Recurrence
Immunotherapy
Therapeutics
Survival Rate
Injections

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Adjuvant therapy in colorectal cancer. A randomized trial comparing radio-chemotherapy and radio-chemotherapy combined with methanol extraction residue of BCG, MER. / Robinson, E.; Bartal, A.; Cohen, Y.; Milstein, David M.; Mekori, T.

In: Biomedicine Express, Vol. 31, No. 1, 1979, p. 8-10.

Research output: Contribution to journalArticle

@article{bba44b68299042f3ab1177811eaadafc,
title = "Adjuvant therapy in colorectal cancer. A randomized trial comparing radio-chemotherapy and radio-chemotherapy combined with methanol extraction residue of BCG, MER",
abstract = "Fifty-three patients with colorectal cancer (Dukes' B 2 and C) were randomized after surgery. One group was treated by radio-and/or chemotherapy and the second by radio-and/or chemotherapy and MER. After 24 and 36 months a significant longer disease free interval, lower recurrence rate and better survival was found in the group treated by radio-chemo-and immunotherapy. Treatment was well tolerated and there were few local side effects from the MER injections. The long time efficacy of this adjuvant treatment whether it increases the cure rate or only delays recurrence requires longer follow-up.",
author = "E. Robinson and A. Bartal and Y. Cohen and Milstein, {David M.} and T. Mekori",
year = "1979",
language = "English (US)",
volume = "31",
pages = "8--10",
journal = "Biomedicine Express",
issn = "0300-0885",
publisher = "Masson Publishing",
number = "1",

}

TY - JOUR

T1 - Adjuvant therapy in colorectal cancer. A randomized trial comparing radio-chemotherapy and radio-chemotherapy combined with methanol extraction residue of BCG, MER

AU - Robinson, E.

AU - Bartal, A.

AU - Cohen, Y.

AU - Milstein, David M.

AU - Mekori, T.

PY - 1979

Y1 - 1979

N2 - Fifty-three patients with colorectal cancer (Dukes' B 2 and C) were randomized after surgery. One group was treated by radio-and/or chemotherapy and the second by radio-and/or chemotherapy and MER. After 24 and 36 months a significant longer disease free interval, lower recurrence rate and better survival was found in the group treated by radio-chemo-and immunotherapy. Treatment was well tolerated and there were few local side effects from the MER injections. The long time efficacy of this adjuvant treatment whether it increases the cure rate or only delays recurrence requires longer follow-up.

AB - Fifty-three patients with colorectal cancer (Dukes' B 2 and C) were randomized after surgery. One group was treated by radio-and/or chemotherapy and the second by radio-and/or chemotherapy and MER. After 24 and 36 months a significant longer disease free interval, lower recurrence rate and better survival was found in the group treated by radio-chemo-and immunotherapy. Treatment was well tolerated and there were few local side effects from the MER injections. The long time efficacy of this adjuvant treatment whether it increases the cure rate or only delays recurrence requires longer follow-up.

UR - http://www.scopus.com/inward/record.url?scp=0018760656&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018760656&partnerID=8YFLogxK

M3 - Article

C2 - 383171

AN - SCOPUS:0018760656

VL - 31

SP - 8

EP - 10

JO - Biomedicine Express

JF - Biomedicine Express

SN - 0300-0885

IS - 1

ER -